The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

UTSW researchers develop blood test to predict liver cancer risk

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

University of Texas Southwestern researchers developed a blood test to predict which nonalcoholic fatty liver disease patients are most likely to develop hepatocellular carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

More cancers being treated with personalized therapies before surgery, National Cancer Database report shows

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
In Brief

Northwell invests $1.2M to develop program to treat tumors with noninvasive targeted ultrasound beams

Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account